ZD-3523

马鲁司特 1H-吲哚-5-羧酰胺,3-[[[2-甲氧基-4-[(2-甲基苯基)磺酰]氨基]羰基]苯基]甲基]-1-甲基-N-(4,4,4-三氟-2-甲基丁基)- Chemical Name: (R)-3-Methoxy-4-[1-methyl-5-[N-(2-methyl-4,4,4-trifluorobutyl)carbamoyl]indol-3-ylmethyl]-N-(2-methylphenylsulfonyl)benzamide; (R)-3-[2-Methoxy-4-[N-(2-methylphenylsulfonyl)carbamoyl]benzyl]-1-methyl-N-(4,4,4-trifluoro-2-methylbutyl)indole-5-carboxamide
CAS No. 136564-68-6, 136564-67-5 (undefined isomer)
项目整合开发状态: Phase II
项目研究机构: AstraZeneca (Originator)
合成路线:A modification of Leimgruber-Batcho synthesis of indoles was employed to convert 3-methyl-4-nitrobenzoic acid (I) to the 3,5-disubstituted indole (V)).In this process,the intermediate enamine (II) was alkylated with the bromobenzoate (III) prior to hydrolysis and reductive cyclization to the indole nucleus.Alkylation of (V) with iodomethane under basic conditions,followed by amide formation using (R)-4,4,4-trifluoro-2-methylbutylamine (VII) afforded the key intermediate amidoester (VIII).Hydrolysis of the methyl ester moiety of (VIII) with aqueous lithium hydroxide,followed by sulfonimide formation gave ZD 3523).
📌 参考资料/链接:
参考文献标题:A process for the preparation of a 3-alkylated indole,intermediates,and a process for the preparation of a derivative thereof
文献作者:Jacobs,R.T.; Costello,G.F.; Brook,S.A.; Harrison,P.J.(AstraZeneca plc)
参考来源:EP 0489547

📄 详细内容


合成路线:The synthesis of the key chiral amine component (VII) is outlined:Conversion of 4,4,4-trifluorobutyric acid (XI) to the corresponding acid chloride and subsequent reaction with the anion derived from the Evans oxazolidinone (XII) yielded the acyloxazolidinone (XIII).Treatment of (XIII) with a strong base such as sodium hexamethyldisilazide and alkylation of the resultant enolate with iodomethane at -35 C afforded a mixture of the diastereomeric acyloxazolidinones (XIV).The desired diastereomer was obtained by crystallization of the crude product.Reductive cleavage of the chiral auxiliary gave the enantiomerically pure alcohol (XV),which was converted in two steps to the desired enantiomerically pure amine hydrochloride (VII).Alternative routes to the amine,such as resolution of racemic 4,4,4-trifluoro-2-methylbutyric acid followed by amide formation and reduction to (VII) could also be utilized.

参考文献标题:A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine,intermediates and a process for the preparation of a derivative thereof
文献作者:Jacobs,R.T.; Yee,Y.K.; Bernstein,P.R.; Brewster,A.G.; Sependa,G.J.(AstraZeneca plc)
参考来源:EP 0489548


合成路线:A modification of Leimgruber-Batcho synthesis of indoles was employed to convert 3-methyl-4-nitrobenzoic acid (I) to the 3,5-disubstituted indole (V)).In this process,the intermediate enamine (II) was alkylated with the bromobenzoate (III) prior to hydrolysis and reductive cyclization to the indole nucleus.Alkylation of (V) with iodomethane under basic conditions,followed by amide formation using (R)-4,4,4-trifluoro-2-methylbutylamine (VII) afforded the key intermediate amidoester (VIII).Hydrolysis of the methyl ester moiety of (VIII) with aqueous lithium hydroxide,followed by sulfonimide formation gave ZD 3523).

合成路线:The synthesis of the key chiral amine component (VII) is outlined:Conversion of 4,4,4-trifluorobutyric acid (XI) to the corresponding acid chloride and subsequent reaction with the anion derived from the Evans oxazolidinone (XII) yielded the acyloxazolidinone (XIII).Treatment of (XIII) with a strong base such as sodium hexamethyldisilazide and alkylation of the resultant enolate with iodomethane at -35 C afforded a mixture of the diastereomeric acyloxazolidinones (XIV).The desired diastereomer was obtained by crystallization of the crude product.Reductive cleavage of the chiral auxiliary gave the enantiomerically pure alcohol (XV),which was converted in two steps to the desired enantiomerically pure amine hydrochloride (VII).Alternative routes to the amine,such as resolution of racemic 4,4,4-trifluoro-2-methylbutyric acid followed by amide formation and reduction to (VII) could also be utilized.
参考文献标题:ZD 3523
文献作者:Bernstein,P.R.; Jacobs,R.T.
参考来源:Drugs Fut 1995,20(12),1233


产品链接: CAS No. 136564-68-6››

产品链接: CAS No.136564-67-5››